The failing myocardium. I. Drug management.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001285:Atropine / Q000627:therapeutic use; D001794:Blood Pressure; D001810:Blood Volume; D002302:Cardiac Output; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D005260:Female; D005934:Glucagon / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D009638:Norepinephrine / Q000627:therapeutic use; D010042:Ouabain / Q000627:therapeutic use; D010952:Plasma Substitutes / Q000627:therapeutic use; D012770:Shock, Cardiogenic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
D000317:Adrenergic alpha-Antagonists; D004071:Digitalis Glycosides; D010952:Plasma Substitutes; D010042:Ouabain; D001285:Atropine; D005934:Glucagon; D007545:Isoproterenol; D004298:Dopamine; D009638:Norepinephrine